

**What they do?**

They sell prescription medicine to consumers at cost directly from drug manufacturers by cutting out the middleman.

**Problem**

The high cost of medications in the U.S. prohibits patients from taking them, increasing the rate of morbidity. It is forcing patients into bankruptcy or traveling across the border to Mexico to fill their prescriptions.

**Solution**

By eliminating pharmacy Benefit Managers and Insurance Companies, Patients can save significantly on the cost of their medications. For example, Tadalafil 20mg can cost the patient only \$2 vs. \$1244 charged at the pharmacy.

**Revenue**

RR \$1.0 M 2023  
RR \$3.0M\* 2024 EBITDA \$1.2M\*  
RR- Recurring Revenue  
\*projected

**Team**

The team is highly experienced, with previous experience in owning and managing retail pharmacies.

**Business Model**

Membership Fees- D2C, B2B and Fulfillment

**ASK**

TBD- The founders are seeking a strategic partner and financial sponsor who can help them become the next Unicorn. Therefore, they are open to all deal structures, including a majority equity sale, roll-equity, and a scheduled earnout. The current founders would like to continue working and scaling the company.

**Generic Drug Market Size USA**

US\$ Billions



<https://www.grandviewresearch.com/industry-analysis/us-telehealth-market>

**Market Growth**

Percentage YOY



**To learn more and receive a copy of the CIM Confidential Information Memorandum, please contact us.**



Jack Eskenazi  
+1 (310) 625-7889  
Jack@ahcteam.com



Dr. Allen Nazeri  
+1 (702) 506-3392  
+66 065-782-6542  
Allen@ahcteam.com

If you like to receive similar or specific listings, please email [Allen@pexits.com](mailto:Allen@pexits.com).

If you wish to be removed from any future listings, please reply " REMOVE ME"